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Abstract: Constipation is a signiﬁ  cant problem related to opioid medications used to manage 
pain. This review attempts to outline the latest ﬁ  ndings related to the therapeutic usefulness of a 
μ opioid receptor antagonist, methylnaltrexone in the treatment of opioid-induced constipation. 
The review highlights methylnaltrexone bromide (RelistorTM; Progenics/Wyeth) a quaternary 
derivative of naltrexone, which was recently approved in the United States, Europe and Canada. 
The Food and Drug Administration in the United States approved a subcutaneous injection for 
the treatment of opioid bowel dysfunction in patients with advanced illness who are receiving 
palliative care and when laxative therapy has been insufﬁ  cient. Methylnaltrexone is a peripherally 
restricted, μ opioid receptor antagonist that accelerates oral–cecal transit in patients with opioid-
induced constipation without reversing the analgesic effects of morphine or inducing symptoms 
of opioid withdrawal. An analysis of the mechanism of action and the potential beneﬁ  ts of using 
methylnaltrexone is based on data from published basic research and recent clinical studies.
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Introduction
Morphine and other opioid agonists are potent analgesics that represent the mainstay 
of therapy in the treatment of acute and chronic severe pain. Opioid analgesics work 
by predominantly stimulating μ opioid receptors in the central nervous system (CNS). 
However, constipation is a signiﬁ  cant problem in patients taking opioid agonists for 
pain relief due primarily to their effect on μ opioid receptors located in the periphery 
within the gut itself. This review will focus on one of the currently available μ opioid 
receptor antagonists, speciﬁ  cally methylnaltrexone bromide (RelistorTM; Progenics/
Wyeth), a quaternary derivative of naltrexone which was recently approved by the 
Food and Drug Administration (FDA) as a subcutaneous injection for the treatment 
of opioid bowel dysfunction in patients with advanced illness who are receiving pal-
liative care and when laxative therapy has been insufﬁ  cient.1 The review will provide 
an overview of methylnaltrexone’s ability to promote gastrointestinal (GI) motility 
in patients with opioid-induced constipation without compromising the analgesic 
effects of morphine or stimulating symptoms of opioid withdrawal. The later sections 
of the review will discuss the potential use of methylnaltrexone for the treatment of 
constipation associated with post-operative ileus.
Effect of opioids on gastrointestinal motility
In the CNS the μ opioid receptor is the primary opioid receptor involved in pain 
transmission. Although there is limited evidence to suggest that centrally located μ 
opioid receptors may be involved in the control of GI transit, the dominant effect of 
the μ opioid receptor agonist, morphine, on the GI tract appears to occur via μ opioid 
receptors located peripherally within the gut wall.2,3 Recent evidence has demon-
strated μ opioid receptors in enteric nervous system, speciﬁ  cally the submucosal Clinical and Experimental Gastroenterology 2008:1 50
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and myenteric plexus in association with interstitial cells 
of Cajal. The muscle layers of the small and large intestine 
also have shown μ opioid receptor immunoreactivity. 
For excellent reviews of the anatomical distribution and 
function of the μ opioid receptor in the GI tract the reader 
is referred to Sternini and colleagues.4–6 Within the GI tract 
classical animal experiments demonstrated that morphine, 
fentanyl and met-enkephalin cause inhibition of both the 
longitudinal and circular muscle layers.7 More recent studies 
using a vascularly perfused intestinal segment demonstrated 
that morphine, dermorphin, D-Ala2-D-Met5-enkephalin, FK 
33–824 and dynorphin reduced the frequency of peristaltic 
waves and the maximal ejection pressure.8 From multiple 
studies and clinical experience, a delay in GI transit is a 
well known characteristic of μ opioid receptor agonists 
including morphine, diphenoxylate and loperamide.9 The 
effects of opioids in delaying intestinal transit is species-
dependent and interspecies differences must be taken into 
account when examining the contribution of opioid agonists 
on GI motility. The delay in GI transit with opioid agonists 
occurs through either an inhibition of propulsive motility 
(rat) or a stimulation of non-propulsive or segmental patterns 
of motility in dog and man.10 The in vivo effects of opioid 
agonists to delay GI transit is due to an inhibition of the 
release of acetylcholine as well as to the release of nonad-
renergic-noncholinergic (NANC) neurotransmitters from 
enteric nerves.11 These effects are mediated at least in part via 
μ opioid receptors present on circular muscle motor neurons.12 
Moreover, in the rat ileum, selective agonists of μ (PLO17) 
and κ (U-50488) receptors inhibit neurotransmitter release 
along the ascending excitatory reﬂ  ex pathway.13 A detailed 
review of the literature reveals that δ opioid receptors also are 
involved in the effects of opioids on motility. Delta receptors 
do not regulate the activity of myenteric excitatory motor 
neurons, since selective δ receptor agonists (DPDPE) or 
antagonists (ICI174864) are ineffective.14 However, in the 
circular muscle of the guinea pig and human colon, NANC 
inhibitory motor responses are reduced by activation of δ 
receptors.15,16
In summary, morphine or morphine-like opioid agonists 
induce a delay in GI transit and are involved in the development 
of opioid bowel dysfunction through a mechanism involving 
predominantly μ opioid receptors located within the GI tract.
Opioid bowel dysfunction
Opioid analgesics represent an important therapy for pain 
management, however opioids also have signiﬁ  cant effects 
on GI motility to delay GI transit and cause constipation 
that may be so severe that it can limit pain management. 
Opioids delay GI transit via an inhibition of gastric 
emptying, a slowing of small and large bowel transit and 
an increase in anal sphincter tone due to activation of μ 
opioid receptors located in the GI tract.17–19 As early as 
1917, Trendelenburg demonstrated in an isolated prepara-
tion of guinea-pig small intestine that morphine inhibits 
peristalsis.7 Since then many studies have conﬁ  rmed that 
morphine and related opioids delay transit throughout the 
GI tract via a peripheral mechanism. Although peripherally 
restricted μ opioid receptor agonists such as loperamide 
have been shown to slow GI transit and are useful for the 
treatment of diarrhea9, the constipating effects of morphine 
that acts at both central and peripheral μ opioid receptors is 
a signiﬁ  cant problem in patients receiving morphine for the 
relief of pain. Stimulation of the μ opioid receptors in the 
GI tract by morphine frequently results in unwanted effects 
termed opioid bowel dysfunction. Opioid bowel dysfunction 
is characterized by severe constipation, hard stools, strain-
ing, incomplete evacuation, bloating, abdominal distension, 
and increased gastroesophageal reﬂ  ux.20–22 It is estimated 
that about 40% of patients taking chronic opioids for pain 
develop opioid bowel dysfunction.20 Clearly, the mechanisms 
of opioid bowel dysfunction are complex; however studies 
have shown that gut hypomotility correlates with opioid con-
centration in the enteric nervous system21 and the morphine-
induced inhibition of GI transit results from activation of μ 
opioid receptors in the gut.22 Interestingly, although patients 
develop tolerance to opioid-induced nausea, vomiting and 
sedation, they rarely develop tolerance to the delayed GI 
transit and resulting constipation induced by opioids.23 In 
summary, chronic opioid use for severe pain is associated 
with signiﬁ  cant adverse effects including opioid-induced 
bowel dysfunction characterized by constipation that is often 
not relieved by laxatives.24–26
Therapeutic approaches for treating 
opioid-induced constipation
Laxatives and promotility agents
Until recently the management of opioid-induced bowel 
dysfunction was limited to use of a stimulate laxative such 
as bisacodyl or senna with or without addition of stool 
softeners such as docusate sodium or lactulose24–26 as well 
as increasing dietary ﬁ  ber, increasing ﬂ  uid intake and/or 
suggesting daily exercise whenever possible to treat the con-
stipation. Osmotic laxatives and bulk forming laxatives also 
have been employed in patients with opioid-induced bowel 
dysfunction but they must be used cautiously in patients Clinical and Experimental Gastroenterology 2008:1 51
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requiring ﬂ  uid restriction, bedridden patients or those with 
strictures or partial bowel obstruction.26,27 Often increased 
ﬁ  ber intake or use of bulk laxatives increase pressure in 
the gut, worsening the patient’s pain and increasing their 
discomfort. Promotility agents such as metaclopramide, a 
dopamine D2 receptor antagonist, also are used to accelerate 
GI transit in a subset of patients with delayed GI transit 
suffering from GI autonomic dysfunction.27 Although 
laxatives are beneﬁ  cial in some patients, they are poorly 
effective in most and opioid-induced bowel dysfunction 
persists despite aggressive laxative therapy. Until recently 
laxatives represented the mainstay of therapy for the 
treatment of opioid-induced constipation, despite their 
serious limitations.
Opioid receptor antagonists
In very severe cases of opioid-induced constipation patients 
reduce their use of opioids to alleviate the constipation 
despite the resulting loss of adequate pain relief. The ﬁ  rst 
competitive opioid antagonists that were used to treat opioid 
bowel dysfunction included naloxone, naltrexone and 
nalmefene. While these antagonists were selective for opioid 
receptors, they were not selective for the periphery, and have 
both central and peripheral activity due to their ability to 
cross the blood brain barrier. Although such compounds 
were able to increase laxation in patients with opioid-induced 
constipation, they also were associated with symptoms of 
opioid withdrawal and a marked decrease in adequate pain 
relief due to the effects of the compounds on central μ opi-
oid receptors. Thus the search was initiated for an opioid 
antagonist that possessed the capability of reversing opioid-
induced constipation without reducing the level of analgesia 
or stimulating opioid withdrawal. It was suggested in the 
latter part of the twentieth century that quaternary narcotic 
antagonists might be useful to treat opioid-induced peripheral 
side effects since some of these agents failed to cross the 
blood brain barrier readily.28,29 Quaternary opioid antagonists 
were developed that had increased polarity and decreased 
lipid solubility and a reduced ability to cross the blood brain 
barrier following systemic administration. As a result, these 
compounds bound only to peripheral μ receptors unless 
administered directly into the brain.28,29 Today peripheral μ 
opioid receptor antagonism offers a newly approved class 
of therapeutics for the treatment of constipation associated 
with the long-term use of opioids while preserving centrally 
mediated analgesia.1 A major focus of the subsequent section 
of this review will be the use of methylnaltrexone for the 
treatment of opioid-induced bowel dysfunction, speciﬁ  cally 
severe constipation in patients receiving opioid therapy for 
pain management.
Effect of methylnaltrexone 
in preclinical experimental models
An extensive series of studies were designed to characterize 
the pharmacological profile of methylnaltrexone. Until 
recently, opioid receptor afﬁ  nity was assessed in whole 
rat brain or guinea pig ileum tissue by displacing the 
binding of non-selective opioid antagonists, 3H-etorphine 
or  3H-diprenorphine. These studies revealed that the 
quaternary derivative of naltrexone exhibited only 1% to 
3% of the afﬁ  nity for the μ opioid receptor as naltrexone 
itself.30 Assessment of the affinities and selectivity of 
methylnaltrexone for μ, δ and κ opioid receptors recently 
was performed in cells expressing recombinant human 
opioid receptors as well as in animal tissues expressing 
endogenous opioid receptors. These studies demonstrated 
that the compound displaced opioid binding to μ opioid 
receptors with an afﬁ  nity of 10 nM, and a 3-fold lower 
afﬁ  nity for κ opioid receptors (Ki 30 nM).31 These studies 
also demonstrated that the afﬁ  nity of methylnaltrexone for 
δ opioid receptors is much less (Ki 15.8 μM).31 While initial 
reports indicated that methylnaltrexone had no intrinsic 
opioid agonist activity,28–30 more recent studies comparing it 
against a variety of opioid antagonists demonstrated that the 
compound exhibited weak partial agonist activity at recom-
binant μ and κ opioid receptors (intrinsic activity 10 and 12, 
respectively).31 Using in vitro and in vivo models the effect of 
methylnaltrexone on the GI tract was systematically studied. 
Methylnaltrexone reversed morphine-induced inhibition of 
gut contractility in isolated guinea-pig ileum and human small 
intestine.31,32 A limited number of studies have also suggested 
that there may be endogenous inhibitory opioid tone of the GI 
musculature since methylnaltrexone alone enhanced muscle 
contractility in tissue isolated from the human32 or equine33 GI 
tract. However, effects of methylnaltrexone on electrically-
evoked contraction of guinea pig ileum muscle strips are 
mixed, with methylnaltrexone inhibiting contractions in one 
study31 and exacerbating contractions in another.32 Some of 
these differences may result from differences in electrical cur-
rent applied to the tissue in the two experiments, as well as to 
different levels of endogenous opioid inhibitory tone between 
species. However, whether methylnaltrexone has therapeutic 
potential in other GI disorders characterized by hypomotility 
requires further research. The effect of methylnaltrexone 
on GI transit in vivo demonstrated that methylnaltrexone at 
doses of 1, 3 and 10 mg/kg, administered subcutaneously, Clinical and Experimental Gastroenterology 2008:1 52
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effectively antagonized morphine-induced inhibition of GI 
transit in rats.34 To test the hypothesis that antagonism of the 
effects of opioids in the gut can be accomplished without 
compromising analgesia, experimental models demonstrated 
that subcutaneous administration of methylnaltrexone had 
no effect on morphine-induced analgesia whereas if the 
methylnaltrexone was administered directly into the brain 
there was a marked reduction in analgesia.34,35
In summary, the efficacy of methylnaltrexone to 
antagonize the GI-mediated events effects of morphine 
occurred at doses that failed to antagonize morphine-
induced analgesia. Early preclinical experiments were also 
conducted with methylnaltrexone to ensure that following 
intravenous administration there were no signs or symptoms 
of withdrawal in opioid-tolerant dogs.28 The study found 
that in response to doses of methylnaltrexone as high at 
50 mg/kg there were no symptoms of withdrawal whereas 
signs of withdrawal were noted with doses of naltrexone as 
low as 0.5 mg/kg.28,36
Clinical pharmacology 
of methylnaltrexone
A summary of the efﬁ  cacy and pharmacokinetic characteris-
tics of methylnaltrexone in healthy human subjects, as well 
as patients with advanced illness or on chronic methadone 
treatment are provided in Table 1. With iv or sc delivery, 
methylnaltrexone is rapidly absorbed in a dose-dependent 
manner, with a peak concentration (Cmax) generally reached 
within 20 to 30 minutes (Tmax) and τ1/2 of elimination is 100 to 
130 minutes.37–39 While orally administered methylnaltrexone 
is absorbed in a dose-dependent manner, far less is absorbed 
in general, maximal blood levels are not achieved until almost 
2 hours, and the τ1/2 is around 3 hours.40 The primary path-
ways of metabolism are the conversion to methyl-6-naltrexol 
isomer (5% of the total) and methylnaltrexone sulphate (1.3% 
of the total). N-methylation of methylnaltrexone to naltrexone 
is not a signiﬁ  cant issue.41 The excretion of methylnaltrexone 
is via the urine and feces and approximately 40% to 50% of 
the compound is excreted unchanged in the urine following 
sc or iv. administration.37–39,42,43 Interestingly, following oral 
administration, only a tiny fraction of methylnaltrexone is 
excreted unchanged (0.3% or less).40,44 Almost a 100-fold 
higher dose of oral methylnaltrexone (19.2 mg/kg)40 was 
required to produce maximal plasma concentrations equiva-
lent to those produced by 0.1 mg/kg sc.39 or 0.16 mg/kg iv 
methylnaltrexone.37 Since only a fraction of the methylnal-
trexone was excreted unchanged yet maintained its ability 
to antagonize morphine-induced oral–cecal transit delay 
(Table 1), this suggests that the majority of the compound 
remained in the GI tract instead of being absorbed into the 
bloodstream.40,44 An enteric-coated formulation of methyln-
altrexone was effective orally at only 3.2 mg/kg.44
Clinical efﬁ  cacy studies 
of methylnaltrexone 
for opioid-induced constipation
In early clinical studies, methylnaltrexone was used as a 
pharmacological tool to examine the relative importance of 
peripheral opioid receptor antagonism in modulating opioid-
induced delay in gastric emptying45 as well as oral–cecal 
transit.38 In the ﬁ  rst human study to demonstrate that opioids 
affect gastric emptying via a peripheral mechanism distinct 
from the central analgesic effects of opioids, 11 healthy 
controls were given placebo (saline) plus morphine or 
methylnaltrexone plus morphine in a randomized double-
blind crossover controlled trial.45 The results showed that 
morphine prolonged gastric emptying and that methylnal-
trexone prevented the morphine-induced gastric emptying. 
In 1996, Yuan et al reported that methylnaltrexone blocked 
morphine-induced oral–cecal transit delay with no effect on 
morphine analgesia, demonstrating for the very ﬁ  rst time in 
human that opioid effects on the gut are mediated through 
peripheral μ opioid receptors distinct from those receptors 
located centrally that mediate analgesia.38
This and other studies performed in healthy volunteers 
measured the ability of methylnaltrexone to reverse morphine-
induced oral to cecal transit time using the lactulose hydrogen 
breath test; 38,39,44,46 pain intensity in response to the cold pressor 
test was assessed in one study to measure levels of pain report-
ing in the same subjects.38 Methylnaltrexone administered 
intravenously, orally or subcutaneously reversed the delay in 
oral–cecal transit induced by morphine38,39,44,46 without any effect 
on levels of analgesia.38 Furthermore, in a randomized placebo-
controlled trial, methylnaltrexone administered intravenously 
at a cumulative low dose ranging from 0.015–0.365 mg/kg 
to 11 subjects with chronic methadone-induced constipation 
reversed the opioid-induced increase in GI transit time and 
produce immediate laxation in 91% of patients on day 1 and 
100% of the patients by the morning of the second day of 
dosing43 (Table 1). More recently in one small study and then 
two larger pivotal studies, the effectiveness of methylnaltrexone 
was investigated in patients with advanced illness with a life 
expectancy of less than 6 months, who were receiving palliative 
opioid therapy and had opioid-induced constipation (deﬁ  ned 
as fewer than 3 bowel movements in the preceding week or no 
bowel movement for 2 days). Rescue laxatives were prohibited Clinical and Experimental Gastroenterology 2008:1 53
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from 4 hours before until 4 hours after receiving the injection of 
methylnaltrexone. A double-blind, randomized parallel group, 
dose ranging study was conducted by Portenoy and colleagues 
in 33 adult patients with advanced illness deﬁ  ned as terminal 
or end stage diseases such as advanced metastatic cancer 
or AIDS.47 Methylnaltrexone at doses of 5, 12.5 and 20 mg 
(0.05–0.5 mg/kg sc) induced a bowel movement within 4 hours 
in 33% to 60% of patients; this was reproducible with repeated 
dosing and occurred in the absence of opioid withdrawal or 
loss of adequate pain control. In a larger Phase III study where 
the primary end point was the proportion of patients with a 
rescue-free laxation within 4 hours of receiving the medication, 
the goal was to compare a single, double blind subcutaneous 
dose of methylnaltrexone (0.15 mg/kg or 0.3 mg/kg) versus 
placebo. The double blind dose was followed by an open-label 
4 week dosing period during which time methylnaltrexone 
could be used as needed but no more that 1 dose in a 24-hour 
period. In the double blind period 154 patients were enrolled 
(47 patients received methylnaltrexone 0.15 mg/kg, 55 meth-
ylnaltrexone 0.3 mg/kg and 52 placebo). The results showed 
that 62% of the patients receiving 0.15 mg/kg methylnaltrexone 
and 58% of those receiving 0.3 mg/kg methylnaltrexone had 
a signiﬁ  cantly higher rate of laxation within 4 hours of the 
double-blind dose compared to 14% treated with placebo.41 
Similar results were report in another Phase III study published 
by Thomas and colleagues in 2008.48 A total of 133 patients 
who were using opioids for pain relief for at least 2 weeks and 
were taking laxatives without relief for their opioid-induced 
constipation were randomly assigned to receive either subcu-
taneous methylnaltrexone (0.15 mg/kg, 62 patients) or placebo 
(71 patients) every other day for a week. During the second 
week the dose of the compound could be increased 0.30 mg/kg 
if the patient had 2 or less rescue-free laxations up to day 8. 
The study found that 48% of patients receiving methylnaltrex-
one had a bowel movement within 4 hours of the ﬁ  rst dose 
while only 15% of patients receiving placebo had a bowel 
movement within 4 hours. However, when the patients were 
asked to self assess improvement in their bowel status using a 
Global Clinical Impression of Change (GCIC) Scale after 7 and 
14 days, most patients (73%) reported increased satisfaction 
following methylnaltrexone therapy compared to only 35% of 
patients in the placebo group, suggesting that methylnaltrexone 
improved the constipating symptoms in over 70% of patients. 
An important component of the study was that no signiﬁ  cant 
changes in pain scores were observed and there were no signs 
of opioid withdrawal.48 This and other clinical studies have also 
assessed the occurrence of methylnaltrexone-related adverse 
effects.23,37,43,45,47,48 There was no dose-dependence associated 
with the adverse effects, which were generally gastrointestinal 
in nature (abdominal pain, diarrhea, ﬂ  atulence and nausea) and 
tolerable. In fact, these side effects are common to existing 
treatments for opioid-induced constipation. In a dose-escalating 
study in which methylnaltrexone was iv infused, a few sub-
jects reported transient orthostatic hypotension, that resolved 
quickly.37 The rates of discontinuation due to adverse events 
during the double-blind placebo controlled clinical trials 
described above were comparable for methylnaltrexone (1.2%) 
and placebo (2.4%); no serious adverse effects were attributed 
to methylnaltrexone.
In summary, the results showed that in these speciﬁ  c 
patient groups with advanced illness, methylnaltrexone 
administered subcutaneously, relieved opioid-induced consti-
pation but most importantly did not reduce analgesia or cause 
any symptomatology associated with opioid withdrawal. 
Methylnaltrexone was effective in almost 70% of those 
patients studied, and it is hoped that further clinical studies 
will be performed in patients with less advanced disease. 
In addition to the currently approved subcutaneous route 
of administration for methylnaltrexone, its future develop-
ment involves multiple routes of administration including 
oral/oral enteric-coated oral forms of methylnaltrexone for 
opioid-induced constipation and an intravenous formulation 
for post-operative ileus.
Potential use of methylnaltrexone 
for the treatment of post-operative 
ileus
Although quite different from opioid bowel dysfunction in 
the setting of chronic opioid administration, another common 
condition termed post-operative ileus is a transient impair-
ment of GI motility that routinely develops as a consequence 
of abdominal surgery. Although the pathophysiology of 
post-operative ileus is very complex involving inﬂ  ammatory, 
neural and hormonal mechanisms, there is a signiﬁ  cant phar-
macological component to post-operative ileus. Speciﬁ  cally the 
use of opioid drugs, such as morphine for the management of 
post-operative pain, is well known to exacerbate the severity 
of post-operative ileus (see review49). In fact a retrospective 
study of post-operative ileus patients identiﬁ  ed that the use 
of opioid-based analgesics represent a key risk factor for the 
development of ileus following surgery.50 Usually patients 
recover from post-operative ileus in 1 to 2 days, particularly 
after laparoscopic bowel surgery. However, prolonged and 
untreated post-operative ileus may require nasogastric intuba-
tion and sometimes even parenteral nutrition. The duration 
of ileus following surgery is dependent on which part of the Clinical and Experimental Gastroenterology 2008:1 55
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GI tract is most affected, with the small intestine recovering 
within the ﬁ  rst 24 hours whereas the stomach (24–48 hours) 
and the colon require longer (48–72 hours) recovery periods. 
Certain patients who are less mobile post-surgery have been 
found to be more susceptible to post-operative ileus. Delayed 
gastric emptying and intestinal transit are the main factors 
leading to symptoms of post-operative ileus which include 
abdominal bloating and pain, nausea and vomiting, anorexia, 
and reduced defecation.
In addition to postoperative opioid dosage, the duration 
of post-operative ileus following colorectal surgery also 
is positively correlated with the amount of blood loss and 
surgery time.51 Although the analgesic effects of opioids, 
such as morphine, are predominantly mediated by μ opioid 
receptors in the CNS, the action of morphine to delay GI 
transit involves predominantly activation of μ opioid recep-
tors in the periphery to inhibit enteric reﬂ  exes and suppress 
GI transit.16 Despite the fact that post-operative abnormali-
ties in GI transit are common and can signiﬁ  cantly delay 
a patient’s recovery, the pathophysiological mechanisms 
causing post-operative ileus are incompletely understood.52 
Research from animal studies has shown abdominal sur-
gery stimulates capsaicin-sensitive afferent ﬁ  bers that lead 
to activation of inhibitory efferent pathways and disrupt 
coordinated patterns of GI motility. Evidence is greatest for 
adrenergic receptor mediated pathways that involve alpha2 
receptors located on vagal nerve terminal and postganglionic 
cholinergic nerves in the myenteric plexus that inhibit the 
release of acetylcholine in post-operative ileus.53 Thus neural 
pathways producing post-operative ileus are complex and 
dependent on a number of factors including the magnitude 
and intensity of the stimulus. For example, incision of the 
skin and laparotomy stimulate adrenergic inhibitory neuronal 
pathways,54,55 whereas abdominal surgery with handling of 
the intestine activates supra-spinal pathways that involve 
stimulation of the hypothalamic pituitary adrenal (HPA) 
stress axis and release of corticotrophin-releasing factor 
(CRF).56–58 In addition, non-adrenergic, non-cholinergic 
(NANC) neuronal pathways may also inhibit GI motility. 
Multiple inhibitory NANC neurotransmitters such as nitric 
oxide (NO), calcitonin gene-related peptide (CGRP) and 
vasoactive intestinal polypeptide (VIP) are present within the 
enteric nervous systems, and they too may play an important 
role in the pathogenesis of post-operative ileus.59–61 Recent 
ﬁ  ndings have also shown that manipulation of the bowel 
during surgery induces a marked intestinal inﬂ  ammation 
in rodents.62–65 These studies showed that speciﬁ  c inﬂ  am-
matory cells such as monocytes, neutrophils and mast cells 
increase in response to bowel manipulation, and there was 
a marked induction within the GI musculature of induc-
ible nitric oxide synthase (iNOS) and cyclo-oxygenase-2 
(COX-2) mRNA. The inﬂ  ammatory response induced by 
bowel manipulation also leads to the secretion of a series of 
pro-inﬂ  ammatory cytokines, including interleukin-1β, inter-
leukin-6, tissue necrosis factor-α and monocyte chemotactic 
protein-1. There is also evidence that bowel manipulation 
up-regulates adhesion molecules such as intercellular adhe-
sion molecule-1 (ICAM-1), and that the ICAM-1 antisense 
oligonucleotide ISIS 3082 prevents the development of ileus 
in mice.66 Interestingly, in an animal model of post-operative 
ileus produced by bowel manipulation, the magnitude of 
the inﬂ  ammatory response appeared to be proportional to 
the decrease in GI transit measured in vivo and the loss 
of smooth muscle contractility observed in an organ bath 
preparation.67,68
The development of new pharmacological strategies 
to accelerate the recovery from POI are urgently needed 
because post-surgical GI dysmotility represents a major 
health problem contributing to patient morbidity, prolonged 
hospital stays and increased health care costs. Recently 
positive clinical efﬁ  cacy data obtained with a peripherally 
acting antagonist of the μ opioid receptor, alvimopan, in 
treating the delay in GI transit following surgery led to its 
recent approval by the FDA for treatment of post-operative 
ileus. However, clinical reports related to the efﬁ  cacy 
of methylnaltrexone for the treatment of post-operative 
ileus have been inconclusive to date. In a Phase II trial 
performed in 65 patients with post-operative ileus induced 
by colonic resection, administration of methylnaltrexone 
(0.3 mg/kg, intravenous) after surgery every 6 hours for 
24 hours recovered from post-operative ileus 1 day faster 
than those receiving placebo as assessed by time to ﬁ  rst 
bowel movement, ability to tolerate food and hospital 
discharge.69 However, those ﬁ  ndings were not supported 
by preliminary results from a Phase III trial of 542 patients 
with post-operative ileus; methylnaltrexone administered 
at 12 or 24 mg every 6 hr did not show efﬁ  cacy over 
placebo.70 At the time of this review, a second Phase III 
trial is underway with preliminary results suggesting that 
methylnaltrexone was not different from placebo in treating 
post-operative ileus.70 The reason for these differences in 
clinical efﬁ  cacy between alvimopan and methylnaltrexone 
for the treatment of post-operative ileus remains to be 
determined but while both alvimopan and methylnaltrexone 
share many pharmacological properties, there are a few 
notable differences. Evidence suggests that alvimopan Clinical and Experimental Gastroenterology 2008:1 56
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has inverse agonist activity in the guinea pig ileum assay 
while methylnaltrexone does not.8 If the various condi-
tions associated with post-operative ileus described above 
contribute to impaired GI transit, one can see how an 
antagonist with inverse agonist properties might more 
effectively increase gut motility than one with very weak 
partial agonist activity. Alvimopan also exhibits a slightly 
greater μ/κ opioid receptor selectivity ratio.30
Finally, it has been proposed that P-glycoprotein (P-gp) 
expression in the small intestine may affect the response of 
the small intestine to chronic drug treatment.71 For instance, 
while tolerance does not develop to the constipating effects of 
morphine, tolerance does develop to the inhibitory GI transit 
effects of loperamide. This difference may be attributed to 
the fact that loperamide is a better substrate for P-gp than 
morphine. To date, there are no reports on the afﬁ  nity of 
either methylnaltrexone or alvimopan for P-gp or other drug 
transporters, but expression of these transporters is altered 
(generally reduced) by acute activation of inﬂ  ammatory 
mediators such as iNOS, interleukin-1β, interleukin-6 and 
tumor necrosis factor-α.72–75 Reduced expression of P-gp 
or other drug efﬂ  ux transporters could increase the level of 
drug in the gut tissue and increase its efﬁ  cacy. Finally, the 
lack of efﬁ  cacy of methylnaltrexone for the treatment of 
post-operative ileus may relate to the design of the clinical 
trails, dosage and route of administration, and such factors 
are currently under investigation.
Conclusions and future directions
Although the actions of opioids in the gut have been well 
documented, major gaps remain in our understanding of 
the precise mechanisms underlying these effects, and of 
the potential role of opioid systems in GI diseases. Opioid 
analgesic use is commonly associated with GI side effects 
suggesting a role for opioid systems in both GI function and 
pathophysiology. The use of μ opioid receptor antagonists 
with activity limited to the periphery has proven to be of 
beneﬁ  t in the clinic, where peripherally acting μ opioid 
antagonists, such as methylnaltrexone, reverse the unwanted 
peripheral side effect of constipation associated with opioid 
therapy while preserving centrally mediated opioid analgesia. 
Taken together, the preclinical data on methylnaltrexone are 
consistent with the clinical reports conﬁ  rming the ability of 
methylnaltrexone to antagonize opioid-induced constipa-
tion without reversing analgesia or precipitating withdrawal 
symptoms. Additional research is required to determine 
whether methylnaltrexone also will be useful for the treat-
ment of post-operative ileus.
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